|
1
|
Beger HG, Rau B, Gansauge F, Poch B and
Link KH: Treatment of pancreatic cancer: challenge of the facts.
World J Surg. 27:1075–1084. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kullmann F, Hollerbach S, Dollinger MM,
Harder J, Fuchs M, Messmann H, Trojan J, Gäbele E, Hinke A,
Hollerbach C and Endlicher E: Cetuximab plus
gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic
pancreatic cancer: a multicentre phase II study. Br J Cancer.
100:1032–1036. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Herrmann R, Bodoky G, Ruhstaller T,
Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A,
Pestalozzi B, Köhne CH, Mingrone W, Stemmer SM, Tàmas K, Kornek GV,
Koeberle D, Cina S, Bernhard J, Dietrich D and Scheithauer W; Swiss
Group for Clinical Cancer Research; Central European Cooperative
Oncology Group. Gemcitabine plus capecitabine compared with
gemcitabine alone in advanced pancreatic cancer: a randomized,
multicenter, phase III trial of the Swiss Group for Clinical Cancer
Research and the Central European Cooperative Oncology Group. J
Clin Oncol. 25:2212–2217. 2007. View Article : Google Scholar
|
|
4
|
Bergman AM, Pinedo HM and Peters GJ:
Determinants of resistance to 2′,2′-difluorodeoxycytidine
(gemcitabine). Drug Resist Updat. 5:19–33. 2002.
|
|
5
|
Harris AL: Hypoxia - a key regulatory
factor in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Maxwell PH: The HIF pathway in cancer.
Semin Cell Dev Biol. 16:523–530. 2005. View Article : Google Scholar
|
|
7
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar
|
|
8
|
Huber MA, Kraut N and Beug H: Molecular
requirements for epithelial-mesenchymal transition during tumor
progression. Curr Opin Cell Biol. 17:548–558. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cannito S, Novo E, Compagnone A, Valfrè di
Bonzo L, Busletta C, Zamara E, Paternostro C, Povero D, Bandino A,
Bozzo F, Cravanzola C, Bravoco V, Colombatto S and Parola M: Redox
mechanisms switch on hypoxia-dependent epithelial-mesenchymal
transition in cancer cells. Carcinogenesis. 29:2267–2278. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shah AN, Summy JM, Zhang J, Park SI,
Parikh NU and Gallick GE: Development and characterization of
gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol.
14:3629–3637. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang Z, Li Y, Kong D, Banerjee S, Ahmad A,
Azmi AS, Ali S, Abbruzzese JL, Gallick GE and Sarkar FH:
Acquisition of epithelial-mesenchymal transition phenotype of
gemcitabine-resistant pancreatic cancer cells is linked with
activation of the Notch signaling pathway. Cancer Res.
69:2400–2407. 2009. View Article : Google Scholar
|
|
12
|
Arumugam T, Ramachandran V, Fournier KF,
Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey
DJ and Choi W: Epithelial to mesenchymal transition contributes to
drug resistance in pancreatic cancer. Cancer Res. 69:5820–5828.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hiscox S, Jiang WG, Obermeier K, Taylor K,
Morgan L, Burmi R, Barrow D and Nicholson RI: Tamoxifen resistance
in MCF7 cells promotes EMT-like behaviour and involves modulation
of β-catenin phosphorylation. Int J Cancer. 118:290–301.
2006.PubMed/NCBI
|
|
14
|
Kajiyama H, Shibata K, Terauchi M,
Yamashita M, Ino K, Nawa A and Kikkawa F: Chemoresistance to
paclitaxel induces epithelial-mesenchymal transition and enhances
metastatic potential for epithelial ovarian carcinoma cells. Int J
Oncol. 31:277–283. 2007.
|
|
15
|
Yang AD, Fan F, Camp ER, van Buren G, Liu
W, Somcio R, Gray MJ, Cheng H, Hoff PM and Ellis LM: Chronic
oxaliplatin resistance induces epithelial-to-mesenchymal transition
in colorectal cancer cell lines. Clin Cancer Res. 12:4147–4153.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fuchs BC, Fujii T, Dorfman JD, Goodwin JM,
Zhu AX, Lanuti M and Tanabe KK: Epithelial-to-mesenchymal
transition and integrin-linked kinase mediate sensitivity to
epidermal growth factor receptor inhibition in human hepatoma
cells. Cancer Res. 68:2391–2399. 2008. View Article : Google Scholar
|
|
17
|
Yauch RL, Januario T, Eberhard DA, Cavet
G, Zhu W, Fu L, Pham TQ, Soriano R, Stinson J, Seshagiri S,
Modrusan Z, Lin CY, O’Neill V and Amler LC: Epithelial versus
mesenchymal phenotype determines in vitro sensitivity and predicts
clinical activity of erlotinib in lung cancer patients. Clin Cancer
Res. 11:8686–8698. 2005. View Article : Google Scholar
|
|
18
|
Wang W, Abbruzzese JL, Evans DB, Larry L,
Cleary KR and Chiao PJ: The nuclear factor-κB RelA transcription
factor is constitutively activated in human pancreatic
adenocarcinoma cells. Clin Cancer Res. 5:119–127. 1999.
|
|
19
|
Liptay S, Weber CK, Ludwig L, Wagner M,
Adler G and Schmid RM: Mitogenic and antiapoptotic role of
constitutive NF-κB/relactivity in pancreatic cancer. Int J Cancer.
105:735–746. 2003.PubMed/NCBI
|
|
20
|
Chandler NM, Canete JJ and Callery MP:
Increased expression of NF-κB subunits in human pancreatic cancer
cells. J Surg Res. 118:9–14. 2004.
|
|
21
|
Chandel NS, Trzyna WC, McClintock DS and
Schumacker PT: Role of oxidants in NF-κB activation and TNF-α gene
transcription induced by hypoxia and endotoxin. J Immunol.
165:1013–1021. 2000.
|
|
22
|
Lluis JM, Buricchi F, Chiarugi P, Morales
A and Fernandez- Checa JC: Dual role of mitochondrial reactive
oxygen species in hypoxia signaling: activation of nuclear
factor-κB via c-SRC and oxidant-dependent cell death. Cancer Res.
67:7368–7377. 2007.
|
|
23
|
Yokoi K and Fidler IJ: Hypoxia increases
resistance of human pancreatic cancer cells to apoptosis induced by
gemcitabine. Clin Cancer Res. 10:2299–2306. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rius J, Guma M, Schachtrup C, Akassoglou
K, Zinkernagel AS, Nizet V, Johnson RS, Haddad GG and Karin M:
NF-κB links innate immunity to the hypoxic response through
transcriptional regulation of HIF-1α. Nature. 453:807–811.
2008.
|
|
25
|
Belaiba RS, Bonello S, Zähringer C,
Schmidt S, Hess J, Kietzmann T and Görlach A: Hypoxia up-regulates
hypoxia-inducible factor-1α transcription by involving
phosphatidylinositol 3-kinase and nuclear factor κB in pulmonary
artery smooth muscle cells. Mol Biol Cell. 18:4691–4697. 2007.
|
|
26
|
Huber MA, Azoitei N, Baumann B, Grünert S,
Sommer A, Pehamberger H, Kraut N, Beug H and Wirth T: NF-κB is
essential for epithelial-mesenchymal transition and metastasis in a
model of breast cancer progression. J Clin Invest. 114:569–581.
2004.
|
|
27
|
Shin SR, Sánchez-Velar N, Sherr DH and
Sonenshein GE: 7,12-Dimethylbenz(a)anthracene treatment of a
c-rel mouse mammary tumor cell line induces epithelial to
mesenchymal transition via activation of nuclear factor-κB. Cancer
Res. 66:2570–2575. 2006.PubMed/NCBI
|
|
28
|
Chua HL, Bhat-Nakshatri P, Clare SE,
Morimiya A, Badve S and Nakshatri H: NF-κB represses E-cadherin
expression and enhances epithelial to mesenchymal transition of
mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2.
Oncogene. 26:711–724. 2007.
|
|
29
|
Julien S, Puig I, Caretti E, Bonaventure
J, Nelles L, van Roy F, Dargemont C, de Herreros AG, Bellacosa A
and Larue L: Activation of NF-κB by Akt upregulates Snail
expression and induces epithelium mesenchyme transition. Oncogene.
26:7445–7456. 2007.
|
|
30
|
Wang SJ, Gao Y, Chen H, Kong R, Jiang HC,
Pan SH, Xue DB, Bai XW and Sun B: Dihydroartemisinin inactivates
NF-κB and potentiates the anti-tumor effect of gemcitabine on
pancreatic cancer both in vitro and in vivo. Cancer Lett.
293:99–108. 2010.PubMed/NCBI
|
|
31
|
Kong R, Sun B, Jiang H, Pan S, Chen H,
Wang S, Krissansen GW and Sun X: Downregulation of nuclear
factor-kappaB p65 subunit by small interfering RNA synergizes with
gemcitabine to inhibit the growth of pancreatic cancer. Cancer
Lett. 291:90–98. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Franovic A, Gunaratnam L, Smith K, Robert
I, Patten D and Lee S: Translational up-regulation of the EGFR by
tumor hypoxia provides a non mutational explanation for its
overexpression in human cancer. Proc Natl Acad Sci USA.
104:13092–13097. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang MH, Wu MZ, Chiou SH, Chen PM, Chang
SY, Liu CJ, Teng SC and Wu KJ: Direct regulation of TWIST by HIF-1α
promotes metastasis. Nat Cell Biol. 10:295–305. 2008.
|
|
34
|
Hotz B, Arndt M, Dullat S, Bhargava S,
Buhr HJ and Hotz HG: Epithelial to mesenchymal transition:
expression of the regulators snail, slug, and twist in pancreatic
cancer. Clin Cancer Res. 13:4769–4776. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang B, Zhang Z and Ke Y: Conversion of
cadherin isoforms in cultured human gastric carcinoma cells. World
J Gastroenterol. 12:966–970. 2006.PubMed/NCBI
|
|
36
|
Thiery JP and Sleeman JP: Complex networks
orchestrate epithelial-mesenchymal transitions. Nature Rev Mol Cell
Biol. 7:131–142. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nieto MA: The snail superfamily of
zinc-finger transcription factors. Nat Rev Mol Cell Biol.
3:155–166. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Peinado H, Olmeda D and Cano A: Snail, Zeb
and bHLH factors in tumour progression: an alliance against the
epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Alexander NR, Tran NL, Rekapally H,
Summers CE, Glackin C and Heimark RL: N-cadherin gene expression in
prostate carcinoma is modulated by integrin-dependent nuclear
translocation of Twist1. Cancer Res. 66:3365–3369. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Walmsley SR, Print C, Farahi N,
Peyssonnaux C, Johnson RS, Cramer T, Sobolewski A, Condliffe AM,
Cowburn AS, Johnson N and Chilvers ER: Hypoxia-induced neutrophil
survival is mediated by HIF-1α-dependent NF-κB activity. J Exp Med.
201:105–115. 2005.
|
|
41
|
Carbia-Nagashima A, Gerez J, Perez-Castro
C, Paez-Pereda M, Silberstein S, Stalla GK, Holsboer F and Arzt E:
RSUME, a small RWD-containing protein, enhances SUMO conjugation
and stabilizes HIF-1α during hypoxia. Cell. 131:309–323.
2007.PubMed/NCBI
|
